Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Sponsorship Statement: This continuing medical education activity is sponsored by 
.
Support Statement: There is no commercial support for this activity. The content contained in this activity was developed from the live activity that was supported by an educational grant from 
.
Target Audience: This program is designed for retina specialists, comprehensive ophthalmologists, and other healthcare professionals involved in the treatment of patients with retina disorders.
Learning Objectives: At the conclusion of this activity, participants should be able to:
- Compare short- and long-term efficacy of laser versus antiangiogenic therapy for first and second line treatment of diabetic macular edema.
- Incorporate the most appropriate therapeutic regimen for patients with DME, utilizing dosage regimens that improve long-term anatomic and visual outcomes.
- Assess therapeutic regimens for diabetic macular edema for the occurrence of adverse events and monitor patients appropriately to reduce complications and improve patient satisfaction and quality of life.
Course Chair:
Jeffrey S. Heier, MD
Director, Vitreoretinal Service
Ophthalmic Consultants of Boston
Boston, Massachusetts
Faculty:
David S. Boyer, MD
Clinical Professor of Ophthalmology
University of Southern California
Keck School of Medicine
Retina-Vitreous Associates Medical Group
Los Angeles, California
Carl D. Regillo, MD
Wills Eye Institute
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, Pennsylvania
Andrew P. Schachat, MD
Vice Chairman
Cole Eye Institute
Professor of Ophthalmology
Lerner College of Medicine
Cleveland, Ohio
External Reviewer:
Michael W. Stewart, MD
Continuing Medical Education Information:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of release, December 10, 2012 to December 9, 2013.
How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the lecture, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)TM certificate that will be e-mailed to the participant.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page and the next page.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Planning Committee and Faculty members report the following relationship(s):
Jeffrey S. Heier, MD
Consulting Fees: Genentech, Regeneron, Aerpio Therapeutics, Fovea
Contracted Research: Genentech, Regeneron, Aerpio Therapeutics, Alimera, Fovea
David S. Boyer, MD
Consulting Fees: Regeneron, Spire, Alcon, Allegro, Allergan, Bayer, Eyetech, Genentech, Glaukos, GlaxoSmithKline, iCo Therapeutics, Neurotech, Novartis, Optos, Ora, Pfizer, OCT
Fees for Non-CME Services: Alcon, Allergan, Eyetech, Genentech, iCo Therapeutics, Novartis, Neurotech, Pfizer
Ownership Interest: Allegro
Carl D. Regillo, MD
Consulting Fees: Genentech, Regeneron, Alimera, Allergan
Contracted Research: Genentech, Regeneron, Alimera, Allergan
Andrew P. Schachat, MD
No relevant financial relationships to disclose.
External Reviewer reports the following relationship(s):
Michael W. Stewart, MD
Consulting Fees: Regeneron, Allergan
Contracted Research: Regeneron
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright© 2012 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the United States Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.